Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
US11124577B2 · kind B2 · utility
2Cited by
18References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 2, 2017 |
| Grant date | Sep 21, 2021 |
| Priority date | — |
| Expiry date | Mar 18, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ϵ (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.